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Abstract
Background This study aimed to evaluate the effect of oral dexamethasone in reducing kidney scars in infants with a first febrile
urinary tract infection (UTI).
Methods Children aged between 2 and 24 months with their first presumed UTI, at high risk for kidney scarring based on
procalcitonin levels (≥1 ng/mL), were randomly assigned to receive dexamethasone in addition to routine care or routine care
only. Kidney scars were identified by kidney scan at 6 months after initial UTI. Projections of enrollment and follow-up
completion showed that the intended sample size could not be reached before funding and time to complete the study ran out.
An amendment to the protocol was approved to conduct a Bayesian analysis.
Results We randomized 48 children, of whom 42 had a UTI and 18 had outcome kidney scans (instead of 128 planned). Kidney
scars were found in 0/7 and 2/11 patients in the treatment and control groups respectively. The probability that dexamethasone
could prevent kidney scarring was 99% in the setting of an informative prior probability distribution (which fully incorporated in
the final inference the information on treatment effect provided by previous studies) and 98% in the low-informative scenario
(which discounted the prior literature information by 50%). The probabilities that dexamethasone could reduce kidney scar
formation by up to 20% were 61% and 53% in the informative and low-informative scenario, respectively.
Conclusions Dexamethasone is highly likely to reduce kidney scarring, with a more than 50% probability to reduce kidney scars
by up to 20%.
Trial registration number EudraCT number: 2013-000388-10; registered in 2013 (prospectively registered)
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Kidney scarring can occur in 10 to 40% of children with a
urinary tract infection (UTI) despite appropriate antibiotic
treatment [1, 2]. Infrequently, kidney scarring bears the poten-
tial for long-term sequelae such as hypertension, preeclamp-
sia, and chronic kidney damage, especially in children with an
underlying kidney disease [3–5].
While risk factors are still largely unknown, the inflamma-
tory process, rather than the bacterial component, seems re-
sponsible for the permanent tissue damage of the kidney [6,
7]. On this basis, anti-inflammatory agents, such as steroids,
were studied in animal models showing a reduction in scar
development [8, 9]. One study of children with acute pyelo-
nephritis showed that dexamethasone significantly decreased
urinary levels of interleukin-6 and interleukin-8, suggesting a
possible role in the prevention of scar formation [10].
In 2011, a randomized controlled trial (RCT) including
children with pyelonephritis confirmed on acute 99m-Tc-
dimercaptosuccinic acid (DMSA) scan found that adjuvant
oral methylprednisolone was associated with a lower kidney
scarring rate compared with the control group (33.3% versus
60%). [11] This study, however, included a small sample of
84 children within a wide age range (1 week to 16 years of
age) and had an unbalanced ratio between the study arms (19
patients in the steroid group and 64 in the placebo group). In
addition, the prevalence of kidney scarring was much higher
than previously reported, as it included children with exten-
sive pyelonephritis on acute DMSA scan, which is no longer
recommended in the management of pediatric first febrile
UTIs. Quite recently, Shaikh et al. randomized 546 children
with suspected UTI to adjuvant corticosteroids, confirming
that those treated tended to develop fewer kidney scars than
children who were randomized to receive placebo (9.8% ver-
sus 16.8%) [12]. However, a statistically significant difference
was not achieved, and the study was limited by not reaching
its intended sample size.
Procalcitonin (PCT), a blood biomarker of infection, has
shown good correlation to both acute pyelonephritis and kid-
ney scarring in children [2, 13–16], with approximately 40%
of children with a febrile UTI and PCT values ≥ 1 ng/mL
showing kidney scars on late DMSA scan [2]. The use of
PCT to identify children at high risk of kidney scarring seems
a valuable strategy to select children most likely to benefit
from adjuvant therapies to prevent scarring.
Based on these premises, we conducted a multicenter RCT
to determine the effectiveness of adjuvant steroids in reducing
kidney scar formation in young children with a first febrile
UTI deemed at higher risk for kidney scarring based on their
PCT values. Projections of enrollment and completion of
study follow-up were calculated halfway through the study
because of unanticipated low recruitment and high attrition
rate. As projections showed that the intended sample size
could not be reached before funding and time to complete
the study ran out, an amendment to the analysis plan was
approved to use Bayesian analysis. In Bayesian analyses, the
probability of treatment effect (posterior probability) is esti-
mated considering the trial data and incorporating the prior
probability distribution. The prior distribution includes infor-
mation on treatment effect provided by previous relevant stud-
ies (clinical trials or pilot trials), when available [17].
In this paper, we describe the original study plan and the
study results using a Bayesian analysis approach.
Methods
Study design and participants
This multicenter RCT was conducted at five Italian hospitals.
Three centers (the Ca’ Foncello Hospital of Treviso, the
University Hospital of Padova, and the S. Orsola Hospital of
Bologna), were part of the study since its inception, in
May 2014, while two centers (the hospital of Dolo-Mirano
and the University Hospital of Udine) joined the study in
May 2016. The trial was approved by the Ethics Committee
of the respective institutions and registered with the European
Clinical Trial Database, EudraCT number: 2013-000388-10.
We obtained written informed consent from parents or
guardians.
Children aged 2 to 24 months with the first episode of
presumed febrile UTI at high risk of kidney scarring based
on PCT levels ≥ 1 ng/mL were eligible for enrolment. A pre-
sumed febrile UTI was defined as axillary temperature >
37.5°C and positive dipstick (≥ 1+ leukocyte esterase and/or
nitrites) on urine samples collected by urine catheterization, in
children with unexplained fever and no other signs of
infection.
We excluded children who received antibiotics in 48 h be-
fore evaluation; who had known underlying kidney diseases
or urinary tract abnormalities, a history of previous UTI and
UTI recurrence before DMSA scan at 6 months for detection
of kidney scars, a history of prematurity (birth before 36
weeks of gestational age), known immunodeficit, and contra-
indication to steroid therapy; or whose urine culture eventual-
ly resulted negative. Patients who were hospitalized could be
approached within 48 h after starting antibiotic therapy.
Intervention and randomization
Study participants were randomly allocated to receive dexa-
methasone (0.15 mg/kg per dose every 12 h for 4 days) in
addition to routine care or routine care only. Dexamethasone
could be administered up to 48 h after starting antibiotic ther-
apy in case hospitalized patients could not be approached in
the emergency department. Routine care consisted of oral
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amoxicillin-clavulanate for a total of 10 days for well-
appearing children. In case of allergy or previous adverse
reactions to amoxicillin-clavulanate, cefixime was adminis-
tered. Routine care for ill or toxic-appearing children was
intravenous ceftriaxone followed by oral antibiotic therapy
after the fever had resolved for at least 48 h, for a total 10-
day duration of treatment. Antibiotics could be changed ac-
cording to antibiogram results on positive urine cultures or
ceased if urine cultures resulted negative. The antipyretic of
choice was acetaminophen at all centers, with ibuprofen rec-
ommended only if acetaminophen was ineffective in relieving
the fever-related patient discomfort.
We used a computer-generated randomization list accessed
through a web-based system, which was password-protected.
The computerized system attributed study allocation for each
consecutively enrolled patient (independently of the recruiting
center). An allocation ratio of 1:1, with random block sizes of
12, was used.
Procedures
Quantitative measurements of PCT levels were performed in
blood samples drawn at the time of initial assessment.
Children randomized to the dexamethasone arm received
the oral drop formulation with detailed instructions on the
weight-based dose and times of administration. Patients who
were discharged received a first follow-up call as soon as the
result of the urine culture was available. A diagnosis of UTI
was confirmed in the presence of a positive urine culture de-
fined as the growth of only one micro-organism ≥ 50,000
CFU/mL. In children with a confirmed diagnosis of UTI, a
kidney and bladder ultrasound was recommended as the stan-
dard of care.
A telephone follow-up was also conducted at 10–15 days
after the diagnosis of UTI to survey the compliance with pre-
scribed treatment and the occurrence of any possible adverse
events.
At 6 months after the diagnosis of UTI, a clinical follow-up
visit was performed in conjunction with a DMSA scan to
detect kidney scarring. The DMSA scan was performed ac-
cording to the current European guidelines of the European
Association of Nuclear Medicine [18]. Kidney scarring was
defined as decreased uptake with distortion of the contours or
as cortical thinning with loss of parenchymal volume.
Children with a positive history for UTI recurrence after the
initial episode eventually identified at the 6-month follow-up
were excluded from the study.
Outcomes
The primary outcome was the presence of kidney scars on the
DMSA scan performed at the 6-month follow-up. Outcome
assessors were two nuclear medicine physicians, blinded to
study allocation, and unaware of the patient’s clinical data,
who interpreted the scans independently. Discrepancies were
resolved by consensus if necessary.
Secondary outcomes were the presence of kidney scarring
in the subgroup of children with higher PCT values and the
acceptability of adjuvant steroid treatment in terms of the rate
of discontinuation of treatment and the reported side effects.
Statistical analysis
Original analysis plan
We based the original sample size calculation on the hy-
pothesis that dexamethasone would determine a kidney
scar reduction from 40% (based on the risk associated with
PCT values ≥ 1 ng/mL [2]) to 20%. Sixty-four patients
were required to be randomly assigned to each arm to have
80% power to detect the absolute difference of 20% in scar
frequency between the groups (α = 0.05 for a one-tailed
test). Estimating a 10% rate of patients who did not fulfill
the criteria for UTI diagnosis (i.e., patients with negative or
discordant urine cultures) and 20% of loss to follow-up, a
final number of 92 patients per group were required based
on the Freedman formula. We planned to summarize con-
tinuous variables as medians and interquartile ranges (IQR)
and categorical data as percentages and absolute frequen-
cies. Wilcoxon-type tests were to be used to compare con-
tinuous variables and Pearson chi-square tests, or Fisher
exact tests, as appropriate, for categorical variables, con-
sidering a p-value of 0.05 as statistically significant.
Bayesian analysis plan
Projections of enrollment and completion of study follow-up
showed that the intended sample size could not be reached
before funding and time to complete the study ran out. For
this reason, an amendment to the study protocol was approved
by the participating site Ethics Committes, as well as by the
Italian drugs regulatory authority (AIFA), to conduct a
Bayesian analysis. The Bayesian method allows the incorpo-
ration of the available knowledge on treatment effect (trans-
lated into prior probability distribution), combining it with the
trial data, such as to reduce uncertainty rather than provide a
definitive response to the study hypothesis. The prior proba-
bility distribution is based on biological plausibility and on the
results of other previous relevant studies, or on clinical expe-
rience [17, 19].
The sample size estimation was carried out considering a
Bayesian procedure based on a Beta Binomial model for a
difference in proportion outcome [20]. An average length cri-
terion (ALC) has been considered assuming an interval cov-
erage of 0.9 and a length of 0.35. A Beta prior has been
considered for the computation based on the data from the
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only available RCT, at that time, on the effect of adjuvant
steroids on kidney scarring [11]. Data used for the Beta prior
was the proportion of kidney scarring in both the treatment
and control groups. The probabilities of scarring from the
RCT by Huang et al. [11] are respectively π̂ˆtreat ¼ 0:33
(6|18) and π̂ˆcontrol ¼ 0:66 (39|65). Based on this calculation,
the informative Beta prior has been derived asΠtreat ∼ Beta(6,
12) and Πcontrol ∼ Beta(39, 26). The ALC achieved sample
size consisted of 18 patients (9+9).
A Beta Binomial model was used to analyze the primary
outcome, namely, the difference in scar proportions between
the treatment and control group [21, 22]. The posterior prob-
ability distribution for the difference in proportions outcome
requires the estimation of the posterior distribution of the scar
proportion in each arm, separately, and was computed via
resampling procedure. Given the publication of a recent very
relevant study on the topic [12], we subsequently included the
results of this study in the calculation of the Beta prior prob-
ability distribution, alongside the results of the trial by Huang
et al. [11].
As the inference was expected to be seriously conditioned
by the prior probability distribution (i.e., a priori knowledge
about treatment effect incorporated in the final inference) giv-
en that only a few data points from the study were available to
estimate the likelihood of treatment effect, a sensitivity anal-
ysis was performed to assess the robustness of the inferential
conclusion concerning different prior distributions. In this re-
gard, the prior probability distributions (representing the a
priori knowledge on the treatment effect) considered for the
analysis were as follows:
1. Informative, which fully incorporates in the final infer-
ence the information on the treatment effect provided by
previous relevant published studies [11, 12]
2. Low-informative, which discounts the prior literature in-
formation weight on the final inference by 50%
3. Uninformative, which assumes an absolute lack of a priori
knowledge on the treatment effect estimate
The final results were analyzed evaluating the alternative
hypothesis that the treatment effect estimate (the difference in
the proportions of kidney scar events in treatment versus con-
trol) is less than the hypothesized absolute difference of 20%
in scar frequency between the groups (assuming that steroids
would determine 20% fewer scars compared with the control
group): margin of –0.2. The final results were also evaluated
considering no difference between the groups (absolute differ-
ence of 0%): margin of 0. The analyses were conducted using
R 3.6.2 [23].
Additional details on the Bayesian analysis for this study
have been recently published [24] and are reported as a sum-
mary in the Online Resource 1.
Results
Patient characteristics
Children were recruited between May 2014 and June 2017
and follow-up completed by December 2017. A total of 437
children were assessed for eligibility, of whom 225 (51.5%)
either did not meet inclusion criteria or met exclusion criteria.
Of the remaining 212 patients, 131 (61.8%) did not complete
the study procedures, namely, determination of serum PCT
and/or urine collection through catheterization, to assess eligi-
bility and were considered “potentially eligible.” Of the 81
eligible patients, 12 (14.8%) could not be approached by re-
search staff and 21 (25.9%) declined consent; thus 48 (59.3%)
patients underwent randomization, and 18 completed the 6-
month follow-up for the primary outcome assessment and
were included in the analysis (Fig. 1). The baseline demo-
graphic characteristics of children who were randomized com-
pared with eligible and potentially eligible children were sim-
ilar concerning age, sex, and race (eTable 1- Online Resource
2). The comparison of demographic and clinical characteris-
tics between the treatment and control group did not show
significant differences (Table 1). Enrolled children were most-
ly younger than 1 year of age and presented after a median
duration of fever of 2.5 days. Only one child had a history of
urinary tract abnormality on fetal ultrasound, namely, a mild
pelvic dilatation, which was not confirmed on postnatal ultra-
sound. Urine culture eventually yielded negative results in 6
patients (13%) who were excluded from the study, as per
study protocol. The only isolated organism from positive urine
cultures was E. Coli. Nearly 60% of patients initially received
parenteral antibiotic treatment, and the overall median dura-
tion of treatment was 9.5 days. A total of 10 patients (21%)
underwent a voiding cystourethrography, and vesicoureteral
reflux was found in three. One of these patients had bilateral
reflux and presented recurrent UTIs in the first 6 months after
enrollment, which determined exclusion from the study, as per
study protocol.
The characteristics of children who completed the
follow-up for the determination of the primary outcome
and who were eventually included in the primary analysis
are reported in Table 2. Children who were lost to follow-up
were similar to those with a known outcome (eTable 2-
Online Resource 2).
Primary outcome
Of the 18 recruited patients who completed the follow-up for
the study outcome, 7 were randomized to the adjuvant dexa-
methasone group and 11 to the control group. No kidney scars
on the DMSA scan at 6 months were found in the treatment
group, while two cases of kidney scarring were observed in
Pediatr Nephrol
Table 1 Baseline demographic and clinical characteristics of randomized patients





Age in months 9.4 (5.3–12.3) 7.4 (3.7–13.7) 0.768
Sex (females) 15 (66%) 14 (56%) 0.514
Race (Caucasian) 18 (78%) 22 (88%) 0.481
Urinary tract abnormalities on fetal US 1 (4%) 0 (0%) 0.292
Max body temperature in °C 39.5 (39.3–40.0) 39.3 (38.8–39.8) 0.019
Duration of fever in days 2 (2-4) 3 (2-4) 0.218
Weight in kg 8.5 (7.0–10.0) 8.0 (6.6–10.0) 0.943
Weight percentile by sex/age 50.0 (25.0–90.0) 75.0 (50.0–78.8) 0.552
Height in cm 70.0 (65.5–75.5) 68.0 (65.0–75.0) 0.752
Height percentile by sex/age 75.0 (50.0–90.0) 75.0 (50.0–90.0) 0.772
PCT ng/ml 2.8 (1.4–5.7) 3.1 (1.7–8.1) 0.677
CRP mg/L 15.0 (9.2–75) 17.0 (6.5–46.2) 0.689
Leukocytes n/mm3 17.920 (12.930–23.800) 18.580(14.782–24.555) 0.488
Hemoglobin g/L 11.1 (10.2–11.6) 11.0 (10.2–11.5) 0.783
Urea mg/dL 13.0 (7.3–16.8) 11.0 (8.0–16.0) 0.756
Creatinine mg/dL 0.32 (0.28–0.36) 0.30 (0.28–0.40) 0.850
Leukocyturia on urine dipstick 23 (100%) 24 (96%) 0.332
Nitraturia on urine dipstick 15 (65%) 17 (68%) 0.838
Urine method collection for culture
•Catheterization 22 (96%) 21 (84%) 0.305
•Clean catch 1 (4%) 4 (16%)
Hospitalization 15 (65%) 20 (80%) 0.250
Urine culture positive 20 (87%) 22 (88%) 0.772
Isolated germs on urine culture
•E. coli 20 (87%) 22 (88%) 0.772
•Other germ 0 (0%) 0 (0%)
Antibiotics initially administered 0.282
•Oral
°Amoxicillin-clavulanate 11 (100%) 9 (100%)
•Parenteral
°Ceftriaxone 11 (92%) 13 (81%)
°Amoxicillin-clavulanate 1 (8%) 1 (4%)
°Ampicillin-sulbactam 0 (0%) 2 (8%)
Switch in antibiotics 11 (48%) 14 (56%) 0.570
•Oral 10 (43%) 10 (40%)
°Amoxicillin-clavulanate 6 (60%) 6 (60%) 0.410
°Cefixime 3 (30%) 2 (20%)
°Cefpodoxime 0 (0%) 1 (10%)
°Cefibutene 0 (0%) 1 (10%)
°Other 1 (10%) 0 (0%)
•Parenteral 1 (4%) 4 (16%)
°Ampicillin-sulbactam 0 (0%) 1 (25%)
°Ceftriaxone 1 (100%) 2 (50%) 0.660
°Meropenem 0 (0%) 1 (25%)
Antibiotic therapy duration in days 9 (9–10) 10 (8.25–10) 0.720
Kidney and bladder US performed 18 (78%) 21 (84%) 1.000
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the control arm (Table 3). Figure 2 shows the priors and the
posterior probability distributions, with the probability that the
difference in event rate is less than 0 (i.e., the steroid adjuvant
therapy could prevent the kidney scar events) or –0.2 margin
for each scenario (i.e., the steroid adjuvant therapy could re-
duce kidney scar formation by 20% or more). The probabili-
ties that steroid adjuvant therapy could prevent kidney scar-
ring (differences in proportions less than 0) are very similar
and very high in the informative prior scenario (0.99) and low-
informative prior (0.98), while this probability is smaller in the
uninformative scenario (0.70). Considering a margin of 20%
reduction, based on treatment effect, results differ across sce-
narios. In this case, the probabilities that steroid adjuvant ther-
apy could reduce kidney scar formation by 20% or less are
0.61, 0.53, and 0.45 in the informative, low-informative, and
uninformative setting, while the probabilities of effect beyond
20% reduction in kidney scarring are 0.39, 0.47, and 0.25,
respectively, in the informative, low-informative, and uninfor-
mative setting. Considering also the 95% credibility intervals
(Table 3) for the difference in proportions outcome, the inter-
val includes the zero for the estimates calculated within the
uninformative prior setting, while zero is not included for the
informative and low-informative credibility interval. The –0.2
margin is instead included in all the credibility intervals
(Table 3).
The posterior predictive estimates have been also com-
puted (Table 3). It is possible to assess that the number of
posterior predictive median scar events that could have been
observed if the estimated Bayesian model, which combines
empirical evidence and historical information, was true is
similarly very low in the treatment arm for all prior distri-
butions. For the control group, instead, the median number
of the predictive events is higher in all prior scenarios
showing fewer differences between groups in the uninfor-
mative setting.
Results of the Bayesian analysis showed that a reduction in
the kidney scar event rate is highly likely, when considering
the effect on the final inference of the available knowledge of
the adjuvant steroid therapy synthesized in the informative
and low-informative prior. A preventive effect on the kidney
scar event of adjuvant steroids has not been demonstrated
assuming an absolute lack of a priori knowledge on the treat-
ment effect in a full uninformative prior analysis.
Secondary outcomes
Given the limited number of recruited patients, we were un-
able to assess the frequency of kidney scarring in the subgroup
of children with higher PCT values. As for the acceptability of
adjuvant steroid treatment, 4 out of 22 (18.2%) patients allo-
cated to the dexamethasone group discontinued the treatment.
There was only one reported side effect of transient behavioral
change with reported increased irritability in the treatment
arm.
Discussion
Our study, unfortunately, failed to assess the effectiveness of
adjuvant steroid treatment in reducing kidney scarring in chil-
dren with acute pyelonephritis, as originally designed. Due to
unanticipated significant challenges with patient recruitment
and high attrition rate, we eventually used a Bayesian analysis
approach to estimate the probability of the treatment effect.
Bayesian analysis has been previously used for trials where
difficult recruitment was expected [25]. The Bayesian analysis
Table 1 (continued)





Patients with abnormal findings 9 (50%) 4 (19%)
°Loss of cortico-medullary differentiation 1 0 0.041
°Parenchymal thinning 0 1
°Calyceal dilatation 4 3
°Pelvic dilatation 4 2
°Uretheral dilatation 2 1
°Parenchymal hyperechogenicity 1 0
VCUG 6 (30%) 4 (18%) 0.369
•VUR at MCUG 1 * 2 **
CRP C-reactive protein, VCUG voiding cystourethrography, PCT procalcitonin, US ultrasound, VUR vesicoureteral reflux
*A patient with grade I reflux on the right side
**A patient with grade IV reflux on the left side; a patient with bilateral reflux of grade II on the right side and grade IV on the left side
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in our study showed a 99% probability of any reduction in
kidney scarring in children treated with adjuvant steroids
using an informative prior probability distribution based on
the results of the studies by Huang et al. [11] and by Shaikh
et al. [12] and 98% using a low-informative prior. The prob-
ability of steroid effect decreased to 70% when using an un-
informative prior probability distribution, which assumes an
absolute lack of a priori knowledge on the treatment effect.
However, this assumption, which is the most conservative
within the sensitivity analysis, is the least realistic, as it does
not consider the available published evidence that our results
build upon. The probability that steroid adjuvant therapy
could reduce kidney scar formation by 20% or less was higher
than 50% in the informative and low-informative scenarios
(61% and 53%, respectively), while it decreased to 45% in
the uninformative scenario. Overall, our results go in the same
direction as the two previously published studies on the topic
[11, 12].
The Taiwanese RCT by Huang et al. [11] enrolled a small
sample of children within a wide age range and a high risk of
kidney scarring based on radiologically confirmed extensive
pyelonephritis on acute DMSA scan, with an unbalanced ratio
between the study arms (1:3.4 of treatment versus control
group). These factors likely explain the nearly 50% reduction
Fig. 1 Numbers of children who
were screened, allocated to the
trial group, and included in the
analysis
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in scar development found by this study. The North American
RCT by Shaikh et al. [12], although the largest to date with
254 patients with complete follow-up, failed to reach the
intended sample size of 320 children to detect a 10% absolute
reduction in kidney scarring. The study, which was completed
over 7 years, presents some important differences compared
with ours. It included children within a broader age range
(between 2 months and 6 years), it did not select patients on
the basis of PCT values, it did not exclude children with re-
current UTIs, and it allowed for a broader window for the
assessment of the primary outcome (DMSA scan between 5
and 24 months) and planned a shorter course of dexametha-
sone (3 days instead of 4) at the same daily dosage as in our
study. This study, which included a much larger sample than
ours, encountered some similar challenges. Approximately
50% of eligible patients declined participation, nearly 30%
Table 2 Baseline demographic and clinical characteristics of patients who completed the follow-up for the assessment of the primary outcome





Age in months 10.7 (3.9–16.1) 11.6 (5.1–18.2) 0.964
Sex (females) 3 (43%) 7 (64%) 0.630
Race (Caucasian) 5 (71%) 9 (82%) 0.717
Urinary tract abnormalities on fetal US 1 (14%) 0 (0%) 0.389
Max body temperature in °C 39.5 (39.3–40.0) 39.3 (38.3–39.8) 0.099
Duration of fever in days 2 (2–4) 3 (2–4) 0.376
Weight in kg 7.7 (7.2–10.5) 8.9 (6.5–11.0) 0.856
Weight percentile by sex/age 50.0 (25.0–90.0) 75.0 (50.0–78.8) 0.824
Height in cm 68 (62.0–80.0) 70.0 (62.0–80.0) 0.892
Height percentile by sex/age 50.0 (50.0–90.0) 75.0 (50.0–90.0) 0.852
PCT ng/ml 3.6 (1.3–6.1) 2.3 (1.7–3.3) 0.526
CRP mg/L 15.2 (10.0–115.1) 17.0 (4.1–109) 0.821
Leukocytes n/mm3 19.630 (7.020–29.150) 18.480 (16.800–25.600) 0.441
Hemoglobin g/L 11.1 (10.2–11.7) 11.0 (10.0–11.6) 0.585
Urea mg/dL 14.0 (12.0–35.9) 11.0 (8.0–18.0) 0.266
Creatinine mg/dL 0.38 (0.33–0.50) 0.29 (0.24–0.30) 0.055
Leukocyturia on urine dipstick 6 (86%) 10 (91%) 0.732
Nitraturia on urine dipstick 6 (86%) 9 (82%) 0.829
Urine method collection for culture
•Catheterization 7 (100%) 8 (73%) 0.130
•Clean catch 0 (0%) 3 (27%)
Hospitalization 4 (57%) 9 (82%) 0.255
Antibiotics initially administered 0.464
•Oral
°Amoxicillin-clavulanate 4 (57%) 3 (27%)
•Parenteral
°Ceftriaxone 3 (43%) 7 (64%)
°Ampicillin-sulbactam 0 (0%) 1 (9%)










°Meropenem 0 (0%) 1 (9%)
Antibiotic therapy duration in days 10 (9–10) 10 (8–15) 0.771
Kidney and bladder US performed 5 (71%) 11 (100%)
Abnormal kidney and bladder US 4 (57%) 3 (27%) 0.627
°Parenchymal thinning 0 (0%) 1 (9%)
°Calyceal dilatation 2 (28%) 2 (18%)
°Pelvic dilatation 1 (14%) 2 (18%)
°Uretheric dilatation 1 (14%) 1 (9%)
VCUG 3 (43%) 2 (18%) 0.326
•VUR at VCUG 1 * 1 **
CRP C-reactive protein, VCUG voiding cystourethrography, PCT procalcitonin, US ultrasound, VUR vesicoureteral reflux
*A patient with grade I reflux on the right side
**A patient with grade IV reflux on the left side
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were excluded post-randomization for a negative urine culture
result, and one-third of retained patients failed to complete
follow-up for the assessment of the primary outcome.
Successful recruitment and retention of patients in clinical
trials are known to be some of the greatest challenges in
conducting RCTs. In our trial, we similarly found many bar-
riers to both recruitment and retention. First, adherence to
study procedures by clinicians was a significant challenge to
patient recruitment in our study. Failure to perform blood tests
for PCT determination prevented the assessment of eligibility
for the study, with PCT ≥ 1 ng/mL being one of the inclusion
criteria. Clinicians often felt that determination of blood tests,
although part of local management protocols, was time-
consuming and was of limited added value in well-appearing
previously healthy children with a first uncomplicated UTI
episode. The role and yield of blood markers in the manage-
ment of first febrile UTIs episodes are debatable and are not
routinely recommended by the Italian guidelines, the National
Institute of Care Excellence (NICE), and the American
Academy of Pediatrics (AAP) guidelines [3, 26–29]. While
there is general agreement that blood tests should be per-
formed in infants younger than 2 or 3 months, our study in-
cluded only children older than 2 months. Given the associa-
tion of PCT values with kidney scarring, the inclusion of pa-
tients based on PCT values was considered by experts, at the
time of study design, the best strategy to select patients most
likely to benefit from adjuvant steroid treatment [2, 30]. A
subsequent meta-analysis of individual patient data showed
that children with an abnormal kidney ultrasound or with a
combination of high fever (≥ 39°C) and an etiologic organism
other than E. Coli are at high risk for the development of
kidney scarring [31]. However, all these data are not available
at the time of initial assessment, when the administration of
steroids should be started to maximize their effect during the
acute inflammatory phase. Second, we experienced a high
percentage of declined consent to study participation due to
parental concerns and fear of administering steroids to their
children. This was unanticipated, given the widespread use
and acceptance of steroid administration in asthma and croup
in the acute care setting. However, the 4-day course with a
twice a day administration schedule of dexamethasone may
have induced parents to think this was a high dose treatment
and could have discouraged participation for fear of side ef-
fects. A structured qualitative analysis of parental views and
concerns would have helped to gain an accurate insight into
factors preventing participation in the study. Third, adherence
of participants to study procedures was another main obstacle
to completion of follow-up, which was achieved by only 45%
of enrolled subjects. Parents were reluctant for their children
to undergo the DMSA scan at 6 months, as they had been well
from the initial UTI episode and the exam was perceived as
invasive for their children. In addition, many parents reported
they were discouraged from having their children undergo the
scan, after talking with other physicians. Based on the Italian
guidelines for the management of UTI, published just after our
study protocol was funded and approved [26, 32], a DMSA
scan is recommended in the presence of pre-defined abnor-
malities on ultrasound, clinical risk factors for more severe
infections, or in the case of a second febrile UTI. PCT values
were not mentioned in the guidelines as a risk factor for more
severe infections. While our team completed prior studies,
including a large RCT, on the effectiveness of oral versus
parenteral antibiotics for acute pyelonephritis and diagnostic
accuracy of PCT for acute pyelonephritis and kidney scars [1,
13] DMSA scan at that time was part of the routine manage-
ment of UTIs both acutely and at 6 months, and no additional
treatment was under investigation other than antibiotic thera-
py. Based on the above considerations, it appears very unlike-
ly that another RCT on the effect of adjuvant steroids on
kidney scarring in children could be successfully carried out
in Italy in the future. Similarly, based on the results of the
recent North American study, future RCTs with the same
objective are unlikely to be successfully completed in a rea-
sonable time frame also in settings with higher resources
available for clinical research. However, given the important
potential implications of a cheap and easily implementable
therapy, such as steroids, in improving the health outcomes
of children with UTI, with a potential greater impact in those
children with underlying kidney diseases or urinary tract ab-
normalities, probabilities of effect may be helpful to guide
Table 3 Number and percentages of observed kidney scar events in treatment and control arm. 95% credible intervals are reported for the posterior
distribution πTreat − πControl and for predictive posterior estimates provided in informative, low-informative, and uninformative scenarios
Treatment (n=7) Control (n=11)
0% (0) 18% (2)
Predictive posterior estimates (95% credible
interval)
πTreat−πControl (95% credible interval) P(πtreat−πcontrol<0) P(πtreat−πcontrol< −0.2)
Informative 1 (0 ; 4) 4 (1 ; 7) −0.19 (−0.29 ; −0.06) 0.99 0.39
Low-informative 0 (0 ; 3) 3 (0 ; 7) −0.20 (−0.33 ; −0.03) 0.98 0.47
Uninformative 1 (0 ; 4) 3 (0 ; 7) −0.09 (−0.40 ; 0.25) 0.70 0.25
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clinical practice. With this respect, the Bayesian approach is
able to provide clinicians with probabilities that the clinical
effect lies in a particular range and can be thus used in deci-
sion-making. As reported by Lilford et al. [19], “the strength
of the Bayesian approach is that it produces a probability
distribution which may guide clinical action even when a "de-
finitive" answer is not available…Clinicians are familiar with
the need to make decisions under uncertainty and recommend
the treatment which seems to have the best chance of maxi-
mizing benefit (expected utility) … Nevertheless, a decision
taken on the basis of a posterior belief that includes evidence
from a randomized controlled trial, however small, is more
likely to be correct than a decision based simply on a prior
belief with no evidence from such a trial. Any randomized
evidence is better than none.”
As reported above, our study suffered from many limita-
tions that prevented its completion as per original design. In
addition, some patients may have received one or more doses
of ibuprofen for the treatment of their fever, which might have
had an influence on the study outcome. However, the study
steering committee made a pragmatic choice not to deviate
from the standard of care on fever management at participat-
ing sites to avoid parental confusion with respect to antipyretic
administration for possible future febrile illnesses. In making
this decision, the study steering committee considered that
randomization would equally distribute known and unknown
confounding factors between the study arms. Furthermore, the
study sample size was achieved with respect to the Bayesian
design; however, the allocation in the two treatment groups
appears to be unbalanced (11 versus 7). Despite all these lim-
itations, our Bayesian analysis could provide probabilities of
treatment effect that could be used in clinical practice.
Conclusions
Conducting a trial to assess the effectiveness of adjuvant ste-
roid treatment in reducing kidney scar development in
Fig. 2 Posterior and prior distributions. The probabilities that πTreat − πControl are less than 0 or –0.2 are reported for informative, low-informative, and
uninformative scenarios. π1 = πTreat and π2 = πcontrol
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children with acute pyelonephritis has proven challenging
using a frequentistic approach. A Bayesian analysis approach
showed that adjuvant steroids are very likely to reduce kidney
scarring, with a more than 50% probability to reduce kidney
scar formation by up to 20%, in the setting of an informative
or low-informative prior probability distribution.
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